Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIQUAEMIN SODIUM PRESERVATIVE FREE vs HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin) and Xa, thereby preventing thrombus formation and extension.
Heparin binds to antithrombin III, inducing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (Xa). This prevents the conversion of fibrinogen to fibrin and inhibits clot formation.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, NSTEMI),Prophylaxis of postoperative venous thromboembolism,Anticoagulation for extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass)
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, NSTEMI),Maintenance of patency of IV catheters (in heparin flush solutions),Off-label: Prevention of clotting in extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass)
Intravenous: Initial bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
Continuous intravenous infusion: initial bolus 80 units/kg (max 10,000 units) followed by infusion at 18 units/kg/hour (usual adult dose 1,000-2,000 units/hour). For prophylactic use: subcutaneous 5,000 units every 8-12 hours.
Terminal elimination half-life: 1-2 hours (0.5-1.5 h at therapeutic doses, dose-dependent due to saturable clearance). Context: shorter half-life in pulmonary embolism, prolonged in hepatic/renal impairment. Protamine reversal used for rapid offset.
Dose-dependent: 30–60 min after 25 U/kg IV, 60–90 min after 100 U/kg IV, 150 min after 400 U/kg IV. Terminal half-life: ~1.5 h (low dose) to ~5 h (high dose). Context: nonlinear due to saturable clearance mechanisms.
Cr Cl <30 m L/min: reduce dose by 50% and monitor anti-Xa levels; Cr Cl 30-60 m L/min: reduce dose by 25%; no adjustment for Cr Cl >60 m L/min.
No specific GFR-based dose adjustment; however, reduced clearance may require monitoring of a PTT and dose titration. For severe renal impairment (Cr Cl <30 m L/min), consider dose reduction or alternative agent.
Heparin is contraindicated in patients with a history of heparin-induced thrombocytopenia (HIT) or known hypersensitivity to heparin. Use with extreme caution in patients with major bleeding risk.
Heparin does not cross the placenta. No evidence of teratogenicity in first trimester. Use during second and third trimesters is generally considered safe, but risk of maternal hemorrhage and fetal bleeding exists peripartum.
Heparin does not cross the placenta and is not associated with teratogenicity. No increased risk of fetal malformations in any trimester.
Liquaemin (heparin sodium) is a parenteral anticoagulant; monitor a PTT closely (goal 1.5-2.5x baseline). Protamine sulfate is the reversal agent. Avoid intramuscular injection due to hematoma risk. Use with caution in renal impairment. Heparin-induced thrombocytopenia (HIT) is a serious adverse effect; check platelet counts regularly.
Heparin 1000 units in D5W is typically used as a flush solution to maintain patency of IV catheters; not for therapeutic anticoagulation. Monitor for heparin-induced thrombocytopenia (HIT) with platelet counts. In patients with renal impairment, heparin clearance is unaffected but caution in hepatic disease. Use preservative-free heparin in neonates. Flush with normal saline first if drug incompatibility suspected.
No interactions on record
No interactions on record
LIQUAEMIN SODIUM PRESERVATIVE FREE and HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER are distinct pharmacological agents. LIQUAEMIN SODIUM PRESERVATIVE FREE belongs to the Anticoagulant class and is primarily used for Prophylaxis and treatment of venous thrombosis and pulmonary embolismAtrial fibrillation with embolizationTreatment of acute coronary syndromes (e.g., unstable angina, NSTEMI)Prophylaxis of postoperative venous thromboembolismAnticoagulation for extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass). HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER belongs to the Anticoagulant class and is primarily used for Prophylaxis and treatment of venous thrombosis and pulmonary embolismAtrial fibrillation with embolizationTreatment of acute coronary syndromes (e.g., unstable angina, NSTEMI)Maintenance of patency of IV catheters (in heparin flush solutions)Off-label: Prevention of clotting in extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. LIQUAEMIN SODIUM PRESERVATIVE FREE carries a safety status of Category C, whereas HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Heparin is primarily metabolized by the liver via desulfation and depolymerization; renal clearance of inactive metabolites also occurs.
Heparin is metabolized in the liver and by the reticuloendothelial system; undergoes desulfation and depolymerization. Metabolites are excreted renally.
Renal: 50-70% as unchanged heparin and metabolites via saturable clearance; biliary/fecal: <5% as metabolites.
Renal (minimal, saturable) and reticuloendothelial system (heparinase). Unchanged heparin: negligible urinary excretion. Metabolites: desulfated heparin via hepatic and extrahepatic heparinase; inactive fragments cleared renally.
High: ~90-95%, primarily to antithrombin III, with secondary binding to albumin, fibrinogen, and histidine-rich glycoprotein.
Very high: >90% bound to antithrombin III (AT-III), with additional low-affinity binding to albumin, globulins, fibrinogen, and lipoproteins. Effective free fraction ~5%.
0.05-0.07 L/kg (confined to plasma volume; low Vd due to high protein binding and large molecular size).
0.05–0.07 L/kg (low, primarily confined to plasma). Clinical meaning: reflects limited extravascular distribution; heparin remains largely in plasma and interstitial fluid.
Sub Q: 20-30% (due to binding to endothelial cells and macrophages at injection site). IV: 100%.
Subcutaneous: ~30–50% (dose-dependent, higher with lower doses due to saturable binding). IV: 100%. Not absorbed orally.
Child-Pugh Class B or C: reduce initial dose by 50% and monitor anti-Xa; no data for Class A, use with caution.
Child-Pugh Class A: no adjustment. Class B: reduce initial dose by 25-50% and monitor a PTT. Class C: avoid use due to increased bleeding risk.
Intravenous: 75-100 units/kg bolus, then 20-25 units/kg/hour infusion; subcutaneous: 250 units/kg every 12 hours. Adjust to maintain a PTT 1.5-2.5 times control.
Continuous IV infusion: initial bolus 75-100 units/kg over 10 minutes, then maintenance infusion: infants <1 year: 28 units/kg/hour; children >1 year: 20 units/kg/hour. Titrate to a PTT 60-85 seconds.
Patients >60 years: reduced clearance; lower initial bolus (60 units/kg) and infusion rate (15 units/kg/hour); monitor a PTT and anti-Xa closely.
Elderly patients have altered pharmacokinetics: lower initial bolus (50-60 units/kg) and infusion rate (15 units/kg/hour) recommended due to increased bleeding risk; monitor a PTT closely.
Heparin is not recommended for intramuscular use due to risk of hematoma.
No direct food interactions; however, foods rich in vitamin K (e.g., leafy greens) do not significantly alter heparin efficacy, but maintain consistent intake if on warfarin transition.
No known food interactions. Avoid excessive alcohol consumption as it may increase bleeding risk. Maintain adequate hydration.
Heparin is not excreted into breast milk due to high molecular weight and polarity. Considered compatible with breastfeeding. M/P ratio not applicable.
Heparin is not excreted into breast milk due to its high molecular weight and polarity. Considered compatible with breastfeeding. M/P ratio: not applicable.
Heparin clearance increases in pregnancy due to expanded plasma volume and renal hyperfiltration, often requiring dose increases (20-30% higher weight-based dosing) and monitoring of anti-Xa levels to maintain therapeutic range.
Pregnancy may require higher doses due to increased volume of distribution, renal clearance, and heparin-binding proteins. Monitoring a PTT and adjusting dose to maintain therapeutic levels is recommended; no fixed dose adjustment established.
Report any unusual bleeding or bruising immediately.,Avoid aspirin, NSAIDs, and other anticoagulants unless prescribed.,Inform all healthcare providers you are on heparin.,Do not take any new medications without consulting your doctor.,Use electric razor and soft toothbrush to minimize bleeding risk.
This medication is used to keep your IV line clean and working properly.,Tell your healthcare provider if you have had a reaction to heparin or if you have a history of low platelets.,Report any unusual bleeding, bruising, or signs of allergic reaction (rash, itching, swelling, trouble breathing).,Avoid taking aspirin, ibuprofen, or blood thinners unless prescribed by your doctor.,Inform all healthcare providers that you have an IV line with heparin.